Caleco Pharma Corp.
OTC Bulletin Board : CAEH
FRANKFURT : T3R

Caleco Pharma Corp.

November 23, 2009 08:30 ET

Caleco Pharma Corp. Provides Update on Delivery Of Sample Formulations by Cosmetic Project Management

BELLINGHAM, WASHINGTON--(Marketwire - Nov. 23, 2009) - Caleco Pharma Corp. (the "Company") (OTCBB:CAEH)(FRANKFURT:T3R)(WKN:A0N9Y0) is pleased to announce that Cosmetic Project Management, a Spanish corporation engaged in the business of the formulation, development and commercialization of cosmetic products, will be delivering to the Company the initial samples and formulations of the Natural Hair Care Products (LamiriShampoo, LamiriHair Conditioner, LamiriHair Tonic) and Natural Skin Care Products (LamiriGel and LamiriCreme). The Company anticipates that its approval process and final delivery of the samples and formulations will occur in December 2009.

The Company anticipates that it will use the samples of its Natural Hair Care Products and Natural Skin Care Products for clinical trial purposes. These clinical trials will assist the Company in determining whether there are any dermatological health benefits for hair and skin through the use of its Natural Hair Care Products and Natural Skin Care Products. The Company has entered into initial negotiations with an industry proven and qualified Spanish Clinical Research Organization to assist the Company in designing and developing the Company's proposed clinical trials of the products.

About Caleco Pharma Corp.

The Company's business plan is to develop its proprietary technology designed to treat moderate to severe liver maladies, including Hepatitis C viral infection, (the "Liver Health Formula") as an over-the-counter medication and as a United States Food and Drug Administration ("FDA") approved pharmaceutical. In addition, the Company has also developed or is developing Food Supplements (Lamiridosin), Hair and Dermatological Products (LamiriShampoo, LamiriHair Conditioner, LarimiHair Tonic, LamiriGel and LamiriCreme), Energy Drinks (KTKin) and Chewing Gum (KTK Chewing Gum and KTKids Children Chewing Gum). The formulations of these products are derived from the Company's Liver Health Formula. To date, the Company's intellectual property covering the Liver Health Formula comprises of patent applications in the United States, Europe and Canada and four European Drug Master File applications.

Caleco Pharma Corp. shares are traded in the United States on the OTC Bulletin Board (OTCBB:CAEH) and in Germany on the Frankfurt Stock Exchange (WKN: A0N9Y0/ Symbol: T3R.FSE).

This press release may contain, in addition to historic information, forward-looking statements. These statements may involve known and unknown risks and uncertainties and other factors that may cause the actual results to be materially different from the results implied herein. In particular, there are no assurances that: (i) Cosmetic Project Manufacturing will be able to produce samples of the Company's Natural Hair Care Products and Natural Skin Care Products; (ii) the Company will be able to manufacture or produce its Natural Hair Care Products and Natural Skin Care Products; (iii) the Company will be able to reach an agreement with a clinical research organization to design and develop the Company's proposed clinical trials; (iv) the Company will be able to carry out any pre-clinical or clinical trials of its products; (v) the Company will be able to obtain the requisite product dossiers for its products. Readers are cautioned not to place undue reliance on the forward-looking statements made in this press release.

Caleco Pharma Corp.

John Boschert, President

Contact Information